Pregnant W

Pregnant Women With Polycystic Ovary Syndrome at Risk of Heart Complications During Delivery

Pregnant women with polycystic ovary syndrome (PCOS) appear to have an increased risk of adverse cardiovascular events and pregnancy outcomes at the time of birth, according to a study published in the Journal of the American Heart Association. Adverse outcomes included pre-eclampsia, peripartum cardiomyopathy, heart failure, abnormal heart rhythms, and venous thromboembolism. “Oftentimes, women with PCOS are understandably concerned about the immediate effects, like an irregular menstrual cycle, excess body hair, weight gain, and acne,” said Erin Michos, MD, Johns Hopkins University Sch...

Study compares risk of long COVID associated with delta versus omicron variants of SARS-CoV-2

Findings from a study published in The Lancet suggest reduced odds of long COVID with the severe acu...

Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation an...

A meta-analysis published in the Journal of Hematology and Oncology evaluated the immune responses t...


Suggested videos

Search:
Date
Filters:
Novelties
9:16

Novelties in the diagnosis and management of primary aldosteronism

Presenter: Constantine Stratakis
Cardiology : Hypertension
ESH 2022
Detecting
7:38

Detecting elevated lipoprotein(a) and addressing the ASCVD risks

Presenter: Florian Kronenberg
Cardiology : Atherosclerosis
EAS 2022
Results fr
5:010

Results from the phase 3 PARADIGM trial

Presenter: Yoshino Takayuki
Oncology
ASCO 2022
Pembrolizu
6:32

Pembrolizumab in CRC: What did we learn from the KEYNOTE-177 and the KEYNOTE-651 trials?

Presenter: Richard D. Kim
Oncology
ASCO 2022
Who needs
6:58

Who needs injectable therapies for cholesterol lowering or statins and ezetimibe are enough for CVD prevention?

Presenter: Carl Orringer
Cardiology : Atherosclerosis
EAS 2022
Early brea
6:31

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Presenter: Sibylle Loibl
Oncology : Breast Cancer
ESMO Breast Cancer 2022
The differ
2:47

The difference between the genetic and pharmacological inhibition of PCSK9

Presenter: Giuseppe Danilo Norata
Cardiology : Atherosclerosis
EAS 2022
ESC/EAS jo
10:13

ESC/EAS joint session: What is new in secondary CV prevention?

Presenter: Ulrich Laufs
Cardiology : Atherosclerosis
EAS 2022
Treatment
8:50

Treatment options of chronic urticaria

Presenter: Margarida Gonçalo
Dermatology
EADV Symposium 2022
ESC/EAS jo
6:38

ESC/EAS joint session: Advances in CV risk estimation with focus on dyslipidemia

Presenter: Ian Graham
Cardiology : Atherosclerosis
EAS 2022
Novelties
6:04

Novelties at the International Summit of Lung Cancer in Rome

Presenter: Federico Cappuzzo
Oncology : Lung Cancer
International Summit of Lung Cancer
Atrial fib
19:010

Atrial fibrillation guidelines into clinical practice

Presenter: Daniel Scherr
Cardiology
EHRA 2022
Recent dev
7:02

Recent developments of the conduction system pacing

Presenter: Hung-Fat Tse
Cardiology
EHRA 2022
Conduction
7:07

Conduction system pacing: ready for prime time?

Presenter: Mauro Biffi
Cardiology
EHRA 2022
What do ne
7:17

What do new guidelines tell us about conduction system pacing?

Presenter: Michael Glikson
Cardiology
EHRA 2022
Antithromb
5:33

Antithrombotic Approaches to Reduce the Risk of Secondary Event in CAD and PAD

Presenter: Marc P. Bonaca
Cardiology
ACC 2022
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Long-term
8:46

Long-term efficacy and safety of ixekizumab

Presenter: Andrew Blauvelt
Dermatology
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
Oncology
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
Oncology
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Oncology
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
Oncology
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
Oncology
First-line
7:41

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato
Oncology
Treatment
3:27

Treatment of iron deficiency in acute and chronic heart failure

Presenter: Piotr Ponikowski
Cardiology
Alcohol se
6:32

Alcohol septal ablation in hypertrophic cardiomyopathy: past and future

Presenter: Hubert Seggewiss
Cardiology
The use of
3:35

The use of SGLT2 inhibitors in the prevention and treatment of heart failure

Presenter: Petar M. Seferovic
Cardiology
Direct myo
5:15

Direct myosin inhibitors in hypertrophic cardiomyopathy: a new era?

Presenter: Iacopo Olivotto
Cardiology
Diagnostic
10:55

Diagnostic delay in pulmonary arterial hypertension

Presenter: Barbro Kjellström and Bodil Ivarsson
Clinical I
6:21

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Babak Dehestani
Internal Medicine
Associatio
20:17

Association of GLP 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events

Presenter: Michael Camilleri
Internal Medicine
Liraglutid
13:26

Liraglutide for Weight Management in the Real World

Presenter: Roman Vangoitsenhoven
Cardiology , Diabetology